Effect of Weight Loss on the Growth Hormone Response to Arginine Infusion in Obesity

El-Khodary, Ashraf Z.; Ball, Michael F.; Stein, Barbara; Canary, John J.

doi:10.1210/jcem-32-1-42

Cited by 38 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Informed consent was obtained from all subjects prior to the initiation of the study. Each subject's medical history was elicited, and physical examination was performed on admission to the hospital.…”

Section: Methodsmentioning

confidence: 99%

Digoxin Metabolism in Obesity

et al. 1971

Self Cite

View full text Add to dashboard Cite

A single intravenous dose of tritiated digoxin was given to five obese patients before and after a mean loss of 102 pounds in weight. There were no significant differences in the blood concentrations of digoxin before and after the weight reduction. Likewise, there were no significant differences in the blood concentrations of digoxin when these data were corrected for fat-free body weight.These findings are consistent with the thesis that fat-free body weight is a more important determinant of the blood concentration of digoxin than total body weight is.The clinical implication of this study is that digoxin dosage may be erroneously high if calculated on the basis of total body weight for obese individuals.

show abstract

Section: Methodsmentioning

confidence: 99%

Digoxin Metabolism in Obesity

et al. 1971

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has also been reported that obese subjects display a lack of responsiveness to Ldopa (Fingerhut and Krieger, 1974). It is already known that obese subjects have decreased responsiveness to a variety of other stimuli that induce Gil release in normal subjects such as exercise, postglucose ingestion, sleep, hypoglycemia and arginine infusion (El-Khodary et al, 1971Lessof et al, 1966Quabbe et al, 1971;Roth et al, 1963). Still almost all studies concerning L-dopa and obesity were performed on only few subjects, they did take into consideration only one (Gil) or two parameters and most of them were not well controlled.…”

Section: Introductionmentioning

confidence: 98%

Effect of L-Dopa on Growth Hormone, Glucose, Insulin, and Cortisol Response in Obese Subjects

Vizner¹,

Reiner²,

Sekso³

2009

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Plasma growth hormone, glucose, insulin and cortisol response to oral administration of L-dopa and in insulin-tolerance test were investigated in 18 obese subjects. The results were compared with the results obtained in 10 normal subjects. The obese subjects displayed a lack of growth hormone responsiveness to L-dopa and a diminished GH responsiveness to hypoglycemia. There was no significant difference in glucose response to hypoglycemia in normal and obese subjects. Obese subjects showed normal increments of plasma cortisol following induction of hypoglycemia although there was no consistent cortisol response after L-dopa administration. A blood glucose response following L-dopa administration was seen in most of normal subjects while no increment of blood glucose was noticed in obese subjects.

show abstract

“…In particular obese subjects have basal GH levels lower than normal-weight controls [ 1,2], The GH response to various stimuli is certainly compromised in obesity. In fact in obese subjects subnormal GH levels have been observed during sleep [3], after exercise [4], after administration of arginine [5], Ldopa [6], methoxamine [8], proteins [9], es trogens [5], insulin [10] and human pan creatic GH releasing factor [11,12], The behaviour of prolactin in obesity has been studied to a lesser degree. There is no conclu sive evidence of a central regulatory anom aly of PRL release within obese subjects.…”

Section: Introductionmentioning

confidence: 99%

Effect of Fenfluramine on Growth Hormone and Prolactin Secretion in Obese Subjects

Altomonte¹,

Zoli²,

Alessi³

et al. 1987

Horm Res

View full text Add to dashboard Cite

Obese subjects show a subnormal growth hormone (GH) and prolactin (PRL) release in response to a variety of stimuli. Fenfluramine, an anorexiant drug used in obesity therapy, may have some effects on hypothalamic-pituitary function mediated by serotoninergic stimulation. The present investigation in obese subjects was carried out to study the effects of fenfluramine (60 mg orally) on GH and PRL secretion after intravenous arginine infusion. Ten volunteer obese females were studied and compared with 10 volunteer normal weight controls. In the obese group the GH response to arginine was significantly lower than in control group. Fenfluramine administration restored the subnormal GH response to arginine in obese subjects. The PRL response to arginine in obese women was subnormal. Fenfluramine administration restored the response of PRL to arginine infusion to normal. In conclusion, fenfluramine – under acute circumstances – enhances the hypothalamic-pituitary response to arginine in obese subjects. The decreased GH and PRL output in obese subjects is not due to an absolute hormonal deficiency and this effect of fenfluramine on GH secretion may – due to its lipolysis stimulation – be useful in obesity treatment.

show abstract

Effect of Weight Loss on the Growth Hormone Response to Arginine Infusion in Obesity

Cited by 38 publications

References 0 publications

Digoxin Metabolism in Obesity

Digoxin Metabolism in Obesity

Effect of L-Dopa on Growth Hormone, Glucose, Insulin, and Cortisol Response in Obese Subjects

Effect of Fenfluramine on Growth Hormone and Prolactin Secretion in Obese Subjects

Contact Info

Product

Resources

About